| Kadmon Holdings is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address unmet medical needs, with focus on autoimmune, inflammatory and fibrotic diseases as well as immuno-oncology. Co.'s product candidates are: KD025 is an oral small molecule inhibitor of the Rho-associated coiled-coil kinase 2; KD045, which is a pan-ROCK inhibitor in development for fibrotic diseases; KD033, which is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment; and KD034, which is a formulations of trientine hydrochloride for the treatment of Wilson's disease. The KDMN YTD return is shown above.
The YTD Return on the KDMN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether KDMN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KDMN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.